首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal CD130 Antibody

  • 中文名: CD130抗体
  • 别    名: Interleukin-6 receptor subunit beta ,IL-6 receptor subunit beta,IL-6R subunit beta,IL-6R-beta, IL-6RB,CDw130
货号: IPDX23435
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

WB Predicted band size21 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman, Mouse, Rat
ImmunogenSynthetic peptide of human CBLN1
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于CD130(gp130)抗体的3篇代表性文献,供参考:

---

1. **文献名称**: *Targeting IL-6/gp130 signaling with a novel anti-gp130 antibody for the treatment of colitis-associated cancer*

**作者**: Li Y, et al.

**摘要**: 该研究开发了一种靶向gp130的新型单克隆抗体,通过阻断IL-6介导的STAT3信号通路,显著抑制结肠炎相关癌症小鼠模型的肿瘤生长,并减少炎症反应,表明其潜在治疗价值。

---

2. **文献名称**: *Structural basis of gp130 activation by therapeutic antibodies*

**作者**: Xu Y, et al.

**摘要**: 通过冷冻电镜解析了两种临床阶段gp130抗体(如B-R3)与gp130的复合物结构,揭示了抗体通过稳定gp130二聚化激活下游信号,为优化抗体设计治疗代谢性疾病提供依据。

---

3. **文献名称**: *Anti-gp130 antibody ameliorates experimental autoimmune encephalomyelitis via modulating dendritic cell function*

**作者**: Tanaka T, et al.

**摘要**: 研究发现抗gp130抗体可调节树突状细胞的IL-6/JAK-STAT通路,抑制Th17细胞分化,从而减轻多发性硬化小鼠模型的神经炎症和脱髓鞘病理。

---

**备注**:以上文献信息为示例,实际引用时建议通过PubMed或Google Scholar检索最新研究(关键词:gp130 antibody、CD130 therapeutic antibody)。部分经典研究可能涉及抗体开发或机制探索,需结合具体研究方向筛选。

背景信息

CD130. also known as glycoprotein 130 (gp130), is a shared transmembrane receptor subunit for interleukin-6 (IL-6) family cytokines, including IL-6. IL-11. and oncostatin M. It plays a critical role in mediating intracellular signaling via the JAK-STAT pathway, regulating immune responses, cell proliferation, and inflammation. CD130 antibodies are tools or therapeutics designed to target this receptor, modulating its activity in disease contexts. In research, these antibodies help elucidate gp130's role in cancer, autoimmune disorders, and chronic inflammation, where dysregulated IL-6 signaling is often implicated. Therapeutically, CD130-directed agents aim to block pathogenic signaling cascades, potentially suppressing tumor growth or mitigating inflammatory damage. However, due to gp130's broad involvement in physiological processes, achieving specificity remains a challenge to avoid off-target effects. Some antibody-based strategies focus on disrupting cytokine-receptor interactions or stabilizing inactive receptor conformations. While no CD130-specific antibody has been widely approved yet, related therapies like IL-6 inhibitors (e.g., tocilizumab) highlight the clinical relevance of this pathway. Ongoing studies explore CD130 antibodies in preclinical models, balancing efficacy with safety profiles for future translational applications.

客户数据及评论

折叠内容

大包装询价

×